Shukla Sanjay's Form 4 filing
aTYR PHARMA INCATYR · filed Nov 21, 2022
- Accession no.
- 0001209191-22-058295
- Filed
- Nov 21, 2022
- Trade date
- Nov 21, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $21.4K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shukla SanjayCIK 0001671026 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 21, 2022 | Common Stock | PPurchaseAcquired | +10,000 | $2.14F1 | +$21,400 | 50,798 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents weighted average price for the shares. The shares were purchased at prices ranging from $2.13 to $2.16 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price
Referenced by the price of 1 transaction in Table I.